DUBLIN, Dec. 08, 2014 /PRNewswire/ --Research and Markets

(http://www.researchandmarkets.com/research/dhtvz4/pharmaceutical) has announced the addition of the "Pharmaceutical Market India 2014-2020, Formulations, Active Pharmaceutical Ingredients (APIs), Contract Research and Manufacturing Services (CRAMs), Biosimilars, Generics & Vaccines" report to their offering.

http://photos.prnewswire.com/prnh/20130307/600769

PHARMACEUTICAL MARKET INDIA 2014-2020, Formulations, Active Pharmaceutical Ingredients (APIs), Contract Research and Manufacturing Services (CRAMS), Biosimilars, Generics & Vaccines by Kelly Scientific Publications is a comprehensive report on the pharmaceutical and biotechnology industry in India and its impact on international markets. This report scrutinises top Indian pharmacos and their battle within domestic and international therapeutic markets. The business environment in which they compete is analysed as are key drivers, constraints, challenges and opportunities.

The Indian pharmaceutical market is set to become the eight largest pharma market globally by 2015. In 2012 it was worth $x billion according to the India Brand Equity Foundation (IBEF). It is forecast to reach at least $x billion by 2020 and increase its dominance as a leading player in Asia. It is predicted that the Indian pharma market will be a significant global competitor by 2020 with an expected worth of up to $x billion. This depends on the optimisation of the following submarkets: public health, generics, consumer healthcare drugs, biologics, vaccines and patented products.

This report describes the current therapeutics that are propelling the pharmaceutical and biotechnology markets in India. It examines the current economic climate and how India compares to other emerging markets and also evolved markets such as the US and Europe. Current developments relating to patent expirations, government funding, and regulations are discussed. The emerging trends that appear in key sub-markets such as generics, oncology, cardiovascular, diabetes and vaccines are elucidated and analysed.

This study reveals market figures of the overall Indian pharmaceutical market and sub-markets. It is supported by 333 figures and tables over 183 pages and the reader has the opportunity to re-use and reference these exhibits in their own reports and presentations. Forecast projections and future growth rates are provided to give the reader a forthcoming perspective of this growing industry.

The study also provides a comprehensive financial and product review of key players in the pharmaceutical and biotechnology industry in India. Strategic drivers and restraints of this market are revealed and market opportunities and challenges are identified.

In summary, the Indian biopharmaceutical market has huge opportunities for growth. This industry will significantly affect the international healthcare market and has enormous potential for investment.

Key Topics Covered:

1. Summary

2. Epidemiology and Disease Overview

3. Twelfth Five Year Plan - A Boost for Scientific Research and Development

4. Economic and Business Environment

5. Indian Pharmaceutical Industry

6. Indian Pharmaceutical Company Profiles and Financial Data

7. SWOT Analysis of Indian Pharmaceutical Market

8. Company Directory and Key People

9. Appendix

Companies Mentioned:

• Aurobindo Pharma
• Bharat Serums and Vaccines Ltd
• Biocon Biopharmaceuticals
• Cipla
• Divis Laboratories
• Dr Reddy's Laboratories
• Lupin
• Mankind Pharma
• Panacea Biotech
• Piramal Group
• Ranbaxy Laboratories
• Reliance Life Sciences
• Serum Institute of India
• Sun Pharmaceuticals
• Zydus Cadila

For more information visit http://www.researchandmarkets.com/research/dhtvz4/pharmaceutical

Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net

Related Links

http://www.researchandmarkets.com

SOURCE Research and Markets